5-amino-2-chloro-4-fluoro-3-methyl-N-(2-(4-methylpiperazin-1-yl)-5-(3-(4-(morpholine-4-carbonyl)benzamido)prop-1-yn-1-yl)phenyl)benzamide

ID: ALA4864032

PubChem CID: 164621331

Max Phase: Preclinical

Molecular Formula: C34H36ClFN6O4

Molecular Weight: 647.15

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: Cc1c(F)c(N)cc(C(=O)Nc2cc(C#CCNC(=O)c3ccc(C(=O)N4CCOCC4)cc3)ccc2N2CCN(C)CC2)c1Cl

Standard InChI: InChI=1S/C34H36ClFN6O4/c1-22-30(35)26(21-27(37)31(22)36)33(44)39-28-20-23(5-10-29(28)41-14-12-40(2)13-15-41)4-3-11-38-32(43)24-6-8-25(9-7-24)34(45)42-16-18-46-19-17-42/h5-10,20-21H,11-19,37H2,1-2H3,(H,38,43)(H,39,44)

Standard InChI Key: OKASGPAJFIOSGT-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 46 50  0  0  0  0  0  0  0  0999 V2000
   13.2306   -9.7306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9387  -10.1367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6488   -9.7298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3569  -10.1401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3550  -10.9573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.6449  -11.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9368  -10.9539    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2326   -8.9134    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.5247  -10.1375    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.0628   -9.7332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8166   -9.7272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1065  -10.1341    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4025   -9.7238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4045   -8.9066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1104   -8.4997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8185   -8.9100    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1087  -10.9513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.8127  -11.3616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8148  -12.1788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1048  -12.5857    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3967  -12.1754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3986  -11.3582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1028  -13.4029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1124   -7.6825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1143   -6.8654    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1163   -6.0482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4101   -4.8207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7020   -4.4104    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1160   -4.4138    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.4082   -5.6379    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.0631  -11.3676    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   14.6507   -8.9127    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   14.6429  -12.1814    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7049   -3.5935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9976   -3.1833    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2873   -3.5914    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.2886   -4.4141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.9965   -4.8206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5796   -3.1827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5798   -2.3655    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.8718   -3.5911    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1632   -3.1743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4575   -3.5793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4531   -4.3968    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1605   -4.8077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8724   -4.4011    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  2  7  2  0
  1  8  2  0
  1  9  1  0
  4 10  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 11 16  2  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 17 22  1  0
 20 23  1  0
 12 17  1  0
 24 25  3  0
 25 26  1  0
 27 28  1  0
 27 29  2  0
 27 30  1  0
 26 30  1  0
 15 24  1  0
  9 11  1  0
  5 31  1  0
  3 32  1  0
  6 33  1  0
 28 34  2  0
 34 35  1  0
 35 36  2  0
 36 37  1  0
 37 38  2  0
 38 28  1  0
 36 39  1  0
 39 40  2  0
 39 41  1  0
 41 42  1  0
 41 46  1  0
 42 43  1  0
 43 44  1  0
 44 45  1  0
 45 46  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 647.15	Molecular Weight (Monoisotopic): 646.2471	AlogP: 3.63	#Rotatable Bonds: 6
Polar Surface Area: 120.24	Molecular Species: NEUTRAL	HBA: 7	HBD: 3
#RO5 Violations: 1	HBA (Lipinski): 10	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 1
CX Acidic pKa: ┄	CX Basic pKa: 7.60	CX LogP: 3.80	CX LogD: 3.39
Aromatic Rings: 3	Heavy Atoms: 46	QED Weighted: 0.28	Np Likeness Score: -1.52

References

1. Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X.. (2021) Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity., 223 [PMID:34225179] [10.1016/j.ejmech.2021.113677]
2. Karatas, Hacer H, Townsend, Elizabeth C EC, Bernard, Denzil D, Dou, Yali Y and Wang, Shaomeng S. 2010-07-22 Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. [PMID:20575550]
3. Bolshan, Yuri Y and 16 more authors. 2013-03-14 Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. [PMID:24900672]
4. Getlik, Matthäus M and 17 more authors. 2016-03-24 Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). [PMID:26958703]
5. Li, Dong-Dong DD and 9 more authors. 2016-08-08 Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. [PMID:27116709]
6. Li, Dong-Dong DD and 8 more authors. 2016-11-29 High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. [PMID:27598236]
7. Li, Dong-Dong DD and 5 more authors. 2016-11-15 Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. [PMID:27720555]
8. Wang, Feng F and 17 more authors. 2018-07-12 Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:29889518]
9. Ye, Xiaoqing X and 11 more authors. 2019-02-15 The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. [PMID:30626558]
10. Tian, Jianhua and 24 more authors. 2020-01-23 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. [PMID:31858797]
11. Chacón Simon, Selena and 14 more authors. 2020-04-23 Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:32223236]

5-amino-2-chloro-4-fluoro-3-methyl-N-(2-(4-methylpiperazin-1-yl)-5-(3-(4-(morpholine-4-carbonyl)benzamido)prop-1-yn-1-yl)phenyl)benzamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source